EF-009 for borderline resectable or unresectable pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests an investigational drug called EF-009 for people with pancreatic cancer that is borderline resectable (may be removable after treatment) or unresectable (not removable by surgery). The goal is to see if EF-009 is safe and effective in treating this type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have pancreatic cancer confirmed by a biopsy or other test.
- Your cancer must be borderline removable or not removable (not spread to distant organs).
- You must be in good general health (able to perform daily activities).
- You must have adequate liver, kidney, and blood counts (your doctor will check).
- You must agree to use effective birth control during and after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy regimens (AG and FOLFIRINOX) with an immunotherapy drug (a PD-L1 antibody) before surgery for pancreatic cancer that is borderline resectable or locally advanced. The goal is to shrink the tumor enough to allow successful surgery.
This study tests a new drug (IBI343) combined with chemotherapy given before surgery for pancreatic cancer that is borderline resectable. The goal is to shrink the tumor enough so it can be removed with surgery, and this treatment focuses on a specific marker on cancer cells.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
This trial studies whether adding focused ultrasound (a treatment that uses sound waves to target the tumor) to standard chemotherapy can help shrink or control pancreatic cancer in people whose cancer is borderline resectable or locally advanced. It aims to see if this combination is more effective than chemotherapy alone.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.